From: A comparison of clinical development pathways to advance tuberculosis regimen development
MAMS | BAR | |||
---|---|---|---|---|
Parameters | Phase IIc | Seamless II/III | Phase IIc | Seamless II/III |
Maximum patients | 100 per arm | 400 per arm | 100 per arm | 400 per arm |
Recruitment rate | 10 patients/week | 10 patients/week | ||
Culture and data lag time | 6 weeks | 6 weeks | ||
Proportion of easy/moderate/hard to treat sub-populations | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | ||
Intermediate and surrogate endpoints evaluated | TCC HR | TCC HR TS-52 | TS-8 TS-24 | TS-8 TS-24 TS-52 |
Number of interim analyses | 1–2* | 2–3* | – | – |
Timing of interim analysis | 10–100 patients* | 100–400 patients* | – | – |
Interim criteria | TCC HR threshold: 1.1–2.3* Relapse % threshold: 4–20%* | – | – | |
Equal recruitment period (before adaptive algorithm is initiated) | – | – | 10 patients per arm | 10–50 patients per arm* |
Bayesian adaptive randomization tuning parameters | – | – | Nonaggressive–Aggressive ɣ = 1–25* η = 0.1–2.0* | |
Trial stopping rules | – | – | 4 Arms reach max N | 3 Arms reach max N |
Priors | – | – | – | Optimistic* Skeptical* |